Skip to main content
Premium Trial:

Request an Annual Quote

GenDx Gets Health Canada Approval for HLA Genotyping Test

NEW YORK — Dutch molecular diagnostics firm Genome Diagnostics (GenDx) said on Friday that it has received approval from Canadian regulators for the in vitro diagnostic use of its NGSgo-MX11-3 human leukocyte antigen genotyping test.

NGSgo-MX11-3 provides multiplexed genotyping of 11 HLA loci, using next-generation sequencing and the company's NGSengine software. The genotyping data can be used to help match patients and donors for stem cell transplantation.

Last year, Utrecht-based GenDx received approval from Health Canada for IVD use of two other HLA genotyping tests: NGSgo-AmpX v2 for individual HLA gene amplification and NGSgo-MX6-1 for multiplexed amplification of six HLA genes.

"This latest addition of MX11-3 fits into the trend of applying multiplexed amplification and sequencing of 11 HLA genes of every patient and donor in a single run," GenDx CEO Wietse Mulder said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.